Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

This study has been completed.
Sponsor:
Collaborator:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01398501
First received: July 19, 2011
Last updated: October 3, 2016
Last verified: October 2016